Research & Clinical Trials Awareness Flashcards
7 cards from real AAC practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Research & Clinical Trials Awareness flashcards as text
What is 'precision medicine' in the context of Alzheimer's disease research?
Answer: Tailoring prevention or treatment strategies to an individual's genetic, biomarker, and lifestyle profile
Precision medicine aims to match interventions to the specific biological characteristics of each person, moving beyond a one-size-fits-all approach.
Why might a caregiver be considered a 'study partner' in an Alzheimer's clinical trial?
Answer: To offer an independent assessment of the participant's daily functioning and cognitive changes that the participant may not self-report accurately
Study partners provide critical observational data about the participant's real-world functioning and behavior, which people with cognitive impairment may underreport.
The Dominantly Inherited Alzheimer Network (DIAN) focuses on individuals who carry mutations in genes such as:
Answer: APP, PSEN1, and PSEN2
DIAN studies families carrying autosomal dominant mutations in APP, PSEN1, or PSEN2, which cause rare inherited early-onset Alzheimer's disease.
What does 'open-label extension' mean in the context of an Alzheimer's drug trial?
Answer: A continuation of the trial after the blinded phase ends, where all participants knowingly receive the active treatment
In an open-label extension, both researchers and participants know that the active drug is being administered, typically offered to continue evaluating long-term safety and efficacy.
What is the main scientific rationale behind the 'amyloid cascade hypothesis' that drives many current Alzheimer's clinical trials?
Answer: Accumulation of amyloid-beta plaques is the primary initiating event that drives downstream tau pathology and neurodegeneration
The amyloid cascade hypothesis proposes that abnormal amyloid-beta accumulation is the upstream trigger of Alzheimer's pathology, including tau aggregation and neuronal loss.
In Alzheimer's research, what does the 'NIA-AA research framework' primarily provide?
Answer: A biological definition of Alzheimer's based on ATN biomarkers (Amyloid, Tau, Neurodegeneration) rather than clinical symptoms alone
The NIA-AA 2018 research framework defines Alzheimer's disease biologically using the ATN classification system, enabling earlier and more precise identification of the disease for research purposes.
Which of the following best describes why healthy volunteers sometimes participate in early Alzheimer's clinical trials?
Answer: They establish normal baseline values for biomarkers and help assess safety and tolerability of experimental compounds
Healthy volunteers in Phase I trials help researchers understand a drug's pharmacokinetics and safety profile in people without disease-related confounds.